🔎 Trials Near Me

Home › Kanser sa Dugo › Texas › Dallas

Pag-aaral pangklinika para sa Kanser sa Dugo sa Dallas, TX

Isang pag-aaral para sa Kanser sa Dugo ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Dallas. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Nagre-recruitPhase 1
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT03816345

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Nagre-recruitPhase 2
  • UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT04728893

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Nagre-recruitPhase 3
  • Texas Oncology-Baylor Sammons Cancer Center ( Site 0062), Dallas
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT03486873

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Nagre-recruitPhase 1/2
  • Baylor Scott & White Health, Dallas
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Nagre-recruitPhase 3
  • Texas Oncology-Presbyterian Cancer Center, Dallas
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • Medical City Dallas, Dallas
  • Children's Medical Center Dallas, Dallas
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Nagre-recruitPhase 1
  • UT Southwestern Medical Center, Dallas
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT02074839

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Nagre-recruitPhase 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Edad 2 hanggang 18 · Lahat ng kasarian · Na-update May 5, 2026 · NCT05711667

Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant

Nagre-recruit
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Edad 6 hanggang 29 · Lahat ng kasarian · Na-update May 4, 2026 · NCT04678427

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Nagre-recruitPhase 1
  • UT Southwestern - Simmons Cancer Center, Dallas
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Nagre-recruitPhase 1
  • University of Texas, Southwestern, Dallas
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770

Pag-aaral para sa Kanser sa Dugo sa ibang lungsod

Iba pang pag-aaral sa Dallas

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.